These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 38652242)

  • 1. SARS-CoV-2 infection-induced immune thrombocytopenia: a systematic review of current reports.
    Ono R; Kitagawa I
    Ann Hematol; 2024 Oct; 103(10):3921-3939. PubMed ID: 38652242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dental procedures in 24 patients with chronic immune thrombocytopenia in prospective clinical studies of eltrombopag.
    Tarantino MD; Fogarty PF; Shah P; Brainsky A
    Platelets; 2015; 26(1):93-6. PubMed ID: 24433306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial.
    Bussel JB; Provan D; Shamsi T; Cheng G; Psaila B; Kovaleva L; Salama A; Jenkins JM; Roychowdhury D; Mayer B; Stone N; Arning M
    Lancet; 2009 Feb; 373(9664):641-8. PubMed ID: 19231632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes and management of immune thrombocytopenia secondary to COVID-19: Cleveland clinic experience.
    Kewan T; Gunaratne TN; Mushtaq K; Alayan D; Daw H; Haddad A
    Transfusion; 2021 Jul; 61(7):2014-2018. PubMed ID: 33724474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hemostatic challenges in patients with chronic immune thrombocytopenia treated with eltrombopag.
    Tarantino MD; Bakshi KK; Brainsky A
    Platelets; 2014; 25(1):55-61. PubMed ID: 23402314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thrombopoetin receptor agonist therapy in thrombocytopenia: ITP and beyond.
    Taylor A; Westwood JP; Laskou F; McGuckin S; Scully M
    Br J Haematol; 2017 May; 177(3):475-480. PubMed ID: 28295201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eltrombopag treatment of patients with secondary immune thrombocytopenia: retrospective EHR analysis.
    Patwardhan P; Landsteiner A; Lal LS; Geevarghese L; Le L; Nandal S; Cuker A
    Ann Hematol; 2022 Jan; 101(1):11-19. PubMed ID: 34505942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of eltrombopag for secondary immune thrombocytopenia in clinical practice.
    González-López TJ; Alvarez-Román MT; Pascual C; Sánchez-González B; Fernández-Fuentes F; Pérez-Rus G; Hernández-Rivas JA; Bernat S; Bastida JM; Martínez-Badas MP; Martínez-Robles V; Soto I; Olivera P; Bolaños E; Alonso R; Entrena L; Gómez-Nuñez M; Alonso A; Yera Cobo M; Caparrós I; Tenorio M; Arrieta-Cerdán E; Lopez-Ansoar E; García-Frade J; González-Porras JR
    Br J Haematol; 2017 Sep; 178(6):959-970. PubMed ID: 28573819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of COVID-19 vaccination on platelet counts and bleeding in children, adolescents, and young adults with immune thrombocytopenia.
    Kaicker S; Martinko K; Bussel JB
    Pediatr Blood Cancer; 2023 Jan; 70(1):e30051. PubMed ID: 36317671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune thrombocytopenia and COVID-19: Case report and review of literature.
    Alonso-Beato R; Morales-Ortega A; Fernández FJH; Morón AIP; Ríos-Fernández R; Rubio JLC; Centeno NO
    Lupus; 2021 Aug; 30(9):1515-1521. PubMed ID: 34053365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pediatric refractory acute immune thrombocytopenic purpura secondary to asymptomatic SARS-CoV2].
    Dethier A; Gatineau-Sailliant S; Geurten C; Dresse MF
    Rev Med Liege; 2023 Jul; 78(7-8):393-398. PubMed ID: 37560947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune thrombocytopenia in the setting of acute SARS-CoV-2 infection.
    Caseiro Alves ME; Carmo F; Malato M; Cunha F
    BMJ Case Rep; 2023 Jun; 16(6):. PubMed ID: 37385718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful eltrombopag treatment of severe refractory thrombocytopenia in chronic myelomonocytic leukemia: Two cases reports: A CARE-compliant article.
    Gao Y; Gong M; Zhang C; Kong X; Ma Y
    Medicine (Baltimore); 2017 Oct; 96(43):e8337. PubMed ID: 29069007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eltrombopag safety and efficacy for primary chronic immune thrombocytopenia in clinical practice.
    González-López TJ; Alvarez-Román MT; Pascual C; Sánchez-González B; Fernández-Fuentes F; Jarque I; Pérez-Rus G; Pérez-Crespo S; Bernat S; Hernández-Rivas JA; Andrade MM; Cortés M; Gómez-Nuñez M; Olivera P; Martínez-Robles V; Fernández-Rodríguez A; Fuertes-Palacio MA; Fernández-Miñano C; de Cabo E; Fisac R; Aguilar C; Bárez A; Peñarrubia MJ; García-Frade LJ; González-Porras JR
    Eur J Haematol; 2016 Sep; 97(3):297-302. PubMed ID: 26709028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicentre, randomised phase III study of the efficacy and safety of eltrombopag in Chinese patients with chronic immune thrombocytopenia.
    Yang R; Li J; Jin J; Huang M; Yu Z; Xu X; Zhang X; Hou M
    Br J Haematol; 2017 Jan; 176(1):101-110. PubMed ID: 27734464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eltrombopag therapy in newly diagnosed steroid non-responsive ITP patients.
    Tripathi AK; Shukla A; Mishra S; Yadav YS; Yadav DK
    Int J Hematol; 2014 Apr; 99(4):413-7. PubMed ID: 24526570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eltrombopag for use in children with immune thrombocytopenia.
    Kim TO; Despotovic J; Lambert MP
    Blood Adv; 2018 Feb; 2(4):454-461. PubMed ID: 29487060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura.
    Bussel JB; Cheng G; Saleh MN; Psaila B; Kovaleva L; Meddeb B; Kloczko J; Hassani H; Mayer B; Stone NL; Arning M; Provan D; Jenkins JM
    N Engl J Med; 2007 Nov; 357(22):2237-47. PubMed ID: 18046028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Perioperative oral eltrombopag versus intravenous immunoglobulin in patients with immune thrombocytopenia: a non-inferiority, multicentre, randomised trial.
    Arnold DM; Heddle NM; Cook RJ; Hsia C; Blostein M; Jamula E; Sholzberg M; Lin Y; Kassis J; Larratt L; Tinmouth A; Amini S; Schipperus M; Lim W; Vishnu P; Warner M; Carruthers J; Li N; Lane S; Kelton JG
    Lancet Haematol; 2020 Sep; 7(9):e640-e648. PubMed ID: 32853584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Cost-effectiveness of Eltrombopag for the Treatment of Immune Thrombocytopenia in the United States.
    Tremblay G; Dolph M; Roy AN; Said Q; Forsythe A
    Clin Ther; 2020 May; 42(5):860-872.e8. PubMed ID: 32199608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.